[1]刘玥璘,李险峰,李佳屿,等.宫颈癌组织中DECR1mRNA、AUP1mRNA水平表达与临床病理学特征及预后价值分析研究[J].现代检验医学杂志,2026,41(03):152-157.[doi:10.3969/j.issn.1671-7414.2026.03.027]
　LIU Yuelin,LI Xianfeng,LI Jiayu,et al.Study on mRNA Levels of DECR1 and AUP1 in Cervical Cancer Tissues and Their Association with Clinicopathologic Features and Prognostic Value[J].Journal of Modern Laboratory Medicine,2026,41(03):152-157.[doi:10.3969/j.issn.1671-7414.2026.03.027]
点击复制

宫颈癌组织中DECR1mRNA、AUP1mRNA水平表达与临床病理学特征及预后价值分析研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年03期
页码:
152-157
栏目:
论著
出版日期:
2026-05-13

文章信息/Info

Title:
Study on mRNA Levels of DECR1 and AUP1 in Cervical Cancer Tissues and Their Association with Clinicopathologic Features and Prognostic Value
文章编号:
1671-7414（2026）03-152-06
作者:
刘玥璘1,2，李险峰1，李佳屿3，唐 燕2
1.山西医科大学第一临床医学院，太原 030006;2.四川友谊医院肿瘤科，成都 610011;3.四川省肿瘤医院病理科，成都 610011
Author(s):
LIU Yuelin1,2，LI Xianfeng1，LI Jiayu3，TANG Yan2
1.First Clinical School of Shanxi Medical University, Taiyuan 030006, China;2.Department of Oncology, Sichuan Friendship Hospital, Chengdu 610011, China;3.Department of Pathology, Sichuan Cancer Hospital, Chengdu 610011, China
关键词:
宫颈癌; 2; 4-二烯酰辅酶A还原酶1; 原始广泛存在蛋白1
分类号:
R739.41
DOI:
10.3969/j.issn.1671-7414.2026.03.027
文献标志码:
A
摘要:
目的?分析宫颈癌（CC）组织中2,4-二烯酰辅酶A还原酶1（DECR1）mRNA、原始广泛存在蛋白1（AUP1）mRNA表达与临床病理学特征的关系及预后价值。方法前瞻性选取2017年10月~2022年2月四川友谊医院收治的CC患者105例，采用实时荧光定量聚合酶链反应、免疫组化法检测CC组织及癌旁组织中DECR1mRNA、AUP1mRNA和蛋白表达。分析DECR1mRNA、AUP1mRNA表达与CC患者临床病理学特征的关系。根据CC组织中DECR1mRNA、AUP1mRNA表达均值分为高、低表达组，K-M生存曲线比较不同DECR1mRNA、AUP1mRNA表达CC患者3年无进展生存率，多因素Cox回归分析DECR1mRNA、AUP1mRNA表达与CC患者预后的关系。结果CC组织中DECR1mRNA、AUP1mRNA表达（1.30±0.23、2.52±0.33）高于癌旁组织（0.72±0.12、1.07±0.26），差异具有统计学意义（t=23.463、36.095，均P＜0.001）。CC组织中DECR1蛋白、AUP1蛋白阳性表达率[62.86%（66/105）、60.00%（63/105）]高于癌旁组织[24.76%（26/105）、20.95%（22/105）]，差异具有统计学意义（χ2=30.951、33.224，均P＜0.001）。低分化、FIGO分期Ⅲ期、淋巴结转移DDECR1mRNA（1.37±0.20、1.37±0.20、1.39±0.18）及AUP1mRNA（2.63±0.33、2.63±0.33、2.65±0.33）表达高于中高分化、Ⅰ～Ⅱ期、无淋巴结转移（1.25±0.23、1.26±0.23、1.25±0.23、2.45±0.31、2.46±0.31、2.46±0.31）（t=2.562~3.132，均P＜0.05）。105例CC患者3年无进展生存率为71.43%（75/105），DECR1mRNA、AUP1mRNA高表达CC患者3年无进展生存率[58.00%（29/50）、59.26%（32/54）]低于DECR1mRNA、AUP1mRNA低表达患者[83.64%（46/55）、84.31%（43/51）]（Log-rankχ2=8.319、8.034，均P＜0.05）。FIGO分期Ⅲ期（HR=2.335，95%CI：1.128~4.835）、淋巴结转移（HR=2.318，95%CI：1.115~4.820）、DECR1mRNA≥1.30（HR=3.548，95%CI：1.233~10.209）、AUP1mRNA≥2.52（HR=2.653，95%CI：1.117~6.299）为影响CC患者预后的独立风险因素（均P＜0.05）。结论CC组织中DECR1mRNA、AUP1mRNA高表达与临床病理学特征及不良预后相关，可能成为评估CC预后的新型标志物。
Abstract:
Objective To analyze the expression levels of 2,4-dienoyl-CoA reductase 1 (DECR1) mRNA and ancient ubiquitous protein 1 (AUP1) mRNA in cervical cancer (CC) tissues, and to evaluate their associations with clinicopathologic features and prognostic value of CC patients. Methods A total of 105 patients with CC admitted to Sichuan Friendship Hospital between October 2017 and February 2022 were prospectively enrolled. Real-time quantitative polymerase chain reaction and immunohistochemistry were used to detect the mRNA and protein expression of DECR1 and AUP1 in both CC tissues and adjacent noncancerous tissues. Associations between DECR1 and AUP1 mRNA expression and the clinicopathological characteristics of CC patients were analyzed. Based on the average expression levels of DECR1 and AUP1 mRNA in tumor tissues, patients were divided into high- and low-expression groups. Kaplan-Meier survival analysis was used to compare the 3-year progression-free survival between groups, and multivariate Cox regression analysis was performed to assess the relationship between DECR1 mRNA and AUP1 mRNA expression and patient prognosis. Results DECR1 and AUP1 mRNA levels were significantly higher in CC tissues (1.30 ± 0.23, 2.52 ± 0.33) than in para-tumoral tissues (0.72 ± 0.12, 1.07 ± 0.26), with statistically significant differences (t=23.463, 36.095, both P<0.001). The positive expression rates of DECR1 and AUP1 proteins in CC tissues were 62.86% (66/105) and 60.00% (63/105), respectively, significantly higher than those in adjacent normal tissues [(24.76% (26/105), 20.95% (22/105)], with statistically significant differences (χ2=30.951, 33.224, all P<0.001). Patients with poor differentiation, FIGO stage III, or lymph node metastasis showed higher mRNA levels of DECR1 (1.37 ± 0.20, 1.37 ± 0.20, 1.39 ± 0.18, respectively) and AUP1 (2.63 ± 0.33, 2.63 ± 0.33, 2.65 ± 0.33, respectively) compared to those with moderate-to-high differentiation, stage I-II, or no lymph node metastasis (DECR1: 1.25 ± 0.23，1.26 ± 0.23，1.25 ± 0.23；AUP1：2.45 ± 0.31，2.46 ± 0.31，2.46 ± 0.31), with statistically significant differences (t = 2.562~3.132, all P<0.05). The 3-year progression-free survival (PFS) rate among all patients was 71.43% (75/105). Patients with high DECR1 and AUP1 mRNA expression had significantly lower 3-year progression-free survival rates [58.00% (29/50), 59.26% (32/54)] than those with low DECR1 and AUP1 mRNA expression [83.64% (46/55), 84.31% (43/51)]. Log-rank test showed significant differences (χ2=8.319, 8.034, all P<0.05). Multivariate Cox regression analysis identified FIGO stage III (HR=2.335, 95%CI:1.128~4.835), lymph node metastasis (HR=2.318, 95%CI: 1.115~4.820), DECR1 mRNA ≥ 1.30 (HR=3.548, 95%CI:1.233~10.209), and AUP1 mRNA≥2.52 (HR=2.653, 95%CI: 1.117~6.299) as independent risk factors for poor prognosis (all P<0.05). Conclusions High expression of DECR1 and AUP1 in CC tissues is associated with adverse clinicopathological features and poor prognosis, and may serve as novel biomarkers for assessing CC prognosis.

参考文献/References:

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global can-cer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:a Cancer Journal for Clinicians, 2024, 74(3): 229-263.
[2] WU Y J, HE S Y, CAO M D, et al. Comparative analysis of cancer statistics in China and the United States in 2024[J]. Chinese Medical Journal , 2024, 137(24): 3093-3100.
[3] GU Q Y, WANG Y, YI P, et al. Theoretical framework and emerging challenges of lipid metabolism in can-cer[J]. Seminars in Cancer Biology, 2025, 108: 48-70.
[4] CHEN H Z, LYU F, GAO X S. Advances in ferropto-sis for castration-resistant prostate cancer treatment:novel drug targets and combination therapy strate-gies[J]. Prostate Cancer and Prostatic Diseases, 2024. doi:10.1038/s41391-204-00933-w.
[5] FAN Z, SHUAI H. Strategies for exploring mechanisms of polydatin against NSCLC based on experimentally val-idated network pharmacology and prognostic prediction of lipid metabolism gene expression[J]. International Immu-nopharmacology, 2024, 142, Part B: 113172.
[6] 陈晨.AUP1调节脂代谢诱异脂质堆积在肾透明细胞癌中的作用及机制研究[D].济南:山东大学,2022. CHEN C. The role and mechanism of AUP1 regulating lipid metabolism and inducing lipid accumulation in clear cell renal cell carcinoma[D]. Jinan: Shandong University, 2022.
[7] LIN X F, ZHENG J F, CAI X T, et al. Glycometabolism and lipid metabolism related genes predict the progno-sis of endometrial carcinoma and their effects on tumor cells[J]. BMC Cancer, 2024, 24(1): 571.
[8] BERMUDEZ A, BHATLA N, LEUNG E. Cancer of the cervix uteri[J]. International Journal of Gynaecology and Obstetrics, 2015, 131 Suppl 2: S88-S95.
[9] NASSAR Z D, MAH C Y, DEHAIRS J, et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis[J]. eLife, 2020, 9: e54166.
[10] 张元芬,龙颖,姚德生.嗜神经侵袭与宫颈癌临床病理特征的相关性及对预后的影响[J].中国癌症防治杂志,2025,17(1):109-114. ZHANG Y F, LONG Y, YAO D S. Relationship be-tween perineural invasion and clinical pathological characteristics of cervical cancer and its effects on prognosis[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 109-114.
[11] 赵建芳,石芳,张昕,等.宫颈癌组织中CSRP2BP mRNA,ESRRB mRNA和蛋白水平表达与上皮间质转化及临床预后相关性研究[J].现代检验医学杂志,2024,39(6):96-101, 107. ZHAO J F, SHI F, ZHANG X, et al. Expression of CS-RP2BP mRNA, ESRRB mRNA and protein levels in cervical cancer tissue and their correlation with epithelial mesenchymal transition and clinical prognosis[J]. Journal of Modern Laboratory Medicine, 2024, 39(6): 96-101, 107.
[12] ZENG H M, ZHENG R S, SUN K X, et al. Cancer sur-vival statistics in China 2019-2021:a multicenter,pop-ulation-based study[J]. Journal of the National Cancer Center, 2024, 4(3): 203-213.
[13] 中国优生科学协会阴道镜和宫颈病理学分会,中华医学会妇科肿瘤学分会,中国抗癌协会宫颈癌专业委员会,等.中国子宫颈癌筛查指南(二)[J].现代妇产科进展,2025,34(1):1-9. Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association, Chinese So-ciety of Gynecological Oncology, Chinese Medical Asso-ciation, Chinese Cervical Cancer Society, et al. Guidelines for cervical cancer screening in China Ⅱ[J]. Progress in Obstetrics and Gynecology, 2025, 34(1): 1-9.
[14] MA G F, LIN G L, WANG S T, et al. Prediction of recur-rence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radio-therapy[J]. BMC Women’s Health, 2024, 24(1): 81.
[15] DIN Z U, CUI B, WANG C X, et al. Crosstalk between lipid metabolism and EMT: emerging mechanisms and cancer therapy[J]. Molecular and Cellular Biochemis-try, 2025, 480(1): 103-118.
[16] ALPHEY M S, YU W H, BYRES E, et al. Structure and reactivity of human mitochondrial 2,4-dienoyl-CoA reductase: enzyme-ligand interactions in a distinctive short-chain reductase active site[J]. Journal of Biologi-cal Chemistry, 2005, 280(4): 3068-3077.
[17] ZHAO Y, HAN S B, ZENG Z, et al. Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogram-ming lipid metabolism[J]. Theranostics, 2024, 14(18):7088-7110.
[18] WU S Q, WU X M, WANG Q, et al. Bufalin induces ferroptosis by modulating the 2,4-dienoyl-CoA reduc-tase (DECR1)-SLC7A11 axis in breast cancer[J]. Phy-tomedicine, 2024, 135:156130.
[19] CHENG T, SHAN G Y, YANG H Q, et al. Develop-ment of a ferroptosis-based model to predict prognosis, tumor microenvironment, and drug response for lung adenocarcinoma with weighted genes co-expression network analysis[J]. Frontiers in Pharmacology, 2022, 13: 1072589.
[20] 周慧娟.2,4-二烯酰辅酶A还原酶在甘油三酯分解与宫颈癌细胞增殖中的作用机制[D].安徽:安徽大学, 2021. ZHOU H J. The mechanism of 2,4-dienoyl-CoA reductase affect the lipolysis and accelerate the growth of cervical cancer cells[D]. Anhui: Anhui University, 2021.
[21] HE J Q, WANG X M, CHEN K Y, et al. The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment[J]. Biochemical Pharmacology, 2022, 205: 115241.
[22] ROBICHAUD S, FAIRMAN G, VIJITHAKUMAR V, et al. Identification of novel lipid droplet factors that regulate lipophagy and cholesterol e?ux in macrophage foam cells[J]. Autophagy, 2021, 17(11): 3671-3689.
[23] CHEN C, ZHAO W, LU X X, et al. AUP1 regulates lipid metabolism and induces lipid accumulation to ac-celerate the progression of renal clear cell carcinoma[J]. Cancer Science, 2022, 113(8): 2600-2615.
[24] CHANG P C, LIN Y C, YEN H J, et al. Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in gli-oma[J]. Cancer Cell International, 2023, 23(1): 62.
[25] WANG Y, WU Q, WEI X, et al. Increased immune infiltration and improved prognosis of head and neck squamous cell carcinoma associated with reduced an-cient ubiquitous protein 1 gene expression[J]. Molecu-lar Biotechnology, 2025, 67(5): 1826-1842.
[26] ZHU Y P, YANG W J, WANG X Y, et al. AUP1 tran-scriptionally activated by KDM5B reprograms lipid metabolism to promote the malignant progression of cervical cancer[J]. International Journal of Oncology, 2024, 65(5): 107.
[27] VASSILIOU E, FARIAS-PEREIRA R. Impact of lipid metabolism on macrophage polarization: implications for inflammation and tumor immunity[J]. International Journal of Molecular Sciences, 2023, 24(15): 12032.

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
　TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
　GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
　CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周　静,李　智,周　玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
　ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(03):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[5]徐晓锋,王　纯,卢国丰,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
　XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]高红敏,杨红英,刘　鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
　GAO Hong-min 1,YANG Hong-ying 2,LIU Xin 3.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[7]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
　ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[8]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
　ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(03):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[9]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
　HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(03):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[10]方　芳,吴　玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
　FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]

备注/Memo

备注/Memo:
基金项目：四川省医学青年创新科研项目（编号：Q23093）。
作者简介：刘玥璘（1993-），女，硕士，主治医师，研究方向：宫颈癌，E-mail：18215519691@163.com。
通讯作者：李险峰（1965-），男，硕士，主任医师，研究方向：恶性肿瘤诊疗，E-mail：lixianfeng-lxf@263.net。
更新日期/Last Update: 2026-05-15